Chukwuemeka N Okafor1, Dan J Stein2,3, Lisa Dannatt2, Jonathan Ipser2, Lara J van Nunen2, Marilyn T Lake2,4, Tamar Krishnamurti5, Edythe D London6, Steve Shoptaw2,6,7. 1. Division of Infectious Diseases, David Geffen School of Medicine at University of California, Los Angeles, USA. 2. Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa. 3. South African Medical Research Council Unit on Risk and Resilience in Mental Disorders, Cape Town, South Africa. 4. Department of Psychology, University of Cape Town, Cape Town, South Africa. 5. Division of General Internal Medicine, University of Pittsburgh School of Medicine, University of Pittsburgh, Pittsburgh, USA. 6. Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, USA. 7. Department of Family Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, USA.
Abstract
INTRODUCTION AND AIMS: As South Africa, especially the Western Cape Province, faces an epidemic of methamphetamine use disorder, therapeutic approaches suited to the South African context are needed. This secondary analysis assessed retention and methamphetamine abstinence outcomes in response to an 8-week pilot contingency management (CM) intervention trial of neural correlates of methamphetamine abstinence, exploring sociodemographic and clinical differences between responders and non-responders. DESIGN AND METHODS: Research participants provided thrice-weekly monitored urine samples, which were analysed by qualitative radioimmunoassay. The primary outcome for this analysis was therapeutic response, defined as abstinence from methamphetamine (≥23 of 24 possible methamphetamine-negative urine samples). RESULTS: Data from 30 adults living in Cape Town, South Africa (34 ± 6.1 years of age, mean age ± SD, 21 men) were included. Sixty-three percent (12 men) were responders. In bivariate comparisons, baseline measurements showed fewer responders reported monthly household income ≥25 000+ South African Rand (ZAR; ~USD $1880; vs. ZAR < 25 000) than non-responders (15.8% vs. 63.6%; P = 0.007). Furthermore, responders had higher median years of education (12 vs. 10; Kruskal-Wallis χ2 = 4.25, DF = 1, P = 0.039) and lower median body mass index than non-responders (19 vs. 24; Kruskal-Wallis χ2 = 6.84, P = 0.008). DISCUSSION AND CONCLUSIONS: Therapeutic response in this study were comparable to those obtained with CM for methamphetamine use disorder in North America and Europe. Our findings suggest that CM may be a useful component of treatment strategies to boost retention and continuous abstinence from methamphetamine in Cape Town, South Africa. Larger efficacy studies are needed in this setting.
INTRODUCTION AND AIMS: As South Africa, especially the Western Cape Province, faces an epidemic of methamphetamine use disorder, therapeutic approaches suited to the South African context are needed. This secondary analysis assessed retention and methamphetamine abstinence outcomes in response to an 8-week pilot contingency management (CM) intervention trial of neural correlates of methamphetamine abstinence, exploring sociodemographic and clinical differences between responders and non-responders. DESIGN AND METHODS: Research participants provided thrice-weekly monitored urine samples, which were analysed by qualitative radioimmunoassay. The primary outcome for this analysis was therapeutic response, defined as abstinence from methamphetamine (≥23 of 24 possible methamphetamine-negative urine samples). RESULTS: Data from 30 adults living in Cape Town, South Africa (34 ± 6.1 years of age, mean age ± SD, 21 men) were included. Sixty-three percent (12 men) were responders. In bivariate comparisons, baseline measurements showed fewer responders reported monthly household income ≥25 000+ South African Rand (ZAR; ~USD $1880; vs. ZAR < 25 000) than non-responders (15.8% vs. 63.6%; P = 0.007). Furthermore, responders had higher median years of education (12 vs. 10; Kruskal-Wallis χ2 = 4.25, DF = 1, P = 0.039) and lower median body mass index than non-responders (19 vs. 24; Kruskal-Wallis χ2 = 6.84, P = 0.008). DISCUSSION AND CONCLUSIONS: Therapeutic response in this study were comparable to those obtained with CM for methamphetamine use disorder in North America and Europe. Our findings suggest that CM may be a useful component of treatment strategies to boost retention and continuous abstinence from methamphetamine in Cape Town, South Africa. Larger efficacy studies are needed in this setting.
Authors: Jennifer Plebani Lussier; Sarah H Heil; Joan A Mongeon; Gary J Badger; Stephen T Higgins Journal: Addiction Date: 2006-02 Impact factor: 6.526
Authors: Steven Shoptaw; Alice Huber; James Peck; Xiaowei Yang; Juanmei Liu; John Roll; Benjamin Shapiro; Erin Rotheram-Fuller; Walter Ling Journal: Drug Alcohol Depend Date: 2006-04-18 Impact factor: 4.492
Authors: Wendee M Wechsberg; Hendree E Jones; William A Zule; Bronwyn J Myers; Felicia A Browne; Michelle R Kaufman; Winnie Luseno; Alan J Flisher; Charles D H Parry Journal: Am J Drug Alcohol Abuse Date: 2010-07 Impact factor: 3.829
Authors: Jessica F Magidson; Hetta Gouse; Warren Burnhams; Christie Y Y Wu; Bronwyn Myers; John A Joska; Adam W Carrico Journal: Addict Behav Date: 2016-11-17 Impact factor: 3.913
Authors: Hetta Gouse; John A Joska; Ryan R Lion; Melissa H Watt; Warren Burnhams; Adam W Carrico; Christina S Meade Journal: Drug Alcohol Rev Date: 2015-12-14
Authors: Hetta Gouse; Jessica F Magidson; Warren Burnhams; Jocelyn E Remmert; Bronwyn Myers; John A Joska; Adam W Carrico Journal: PLoS One Date: 2016-01-27 Impact factor: 3.240
Authors: Tamar Krishnamurti; Kimberly Ling Murtaugh; Lara Van Nunen; Alexander L Davis; Jonathan Ipser; Steven Shoptaw Journal: J Subst Abuse Treat Date: 2020-01-25
Authors: Lara J van Nunen; Marilyn T Lake; Jonathan C Ipser; Dan J Stein; Steven J Shoptaw; Edythe D London Journal: J Alcohol Drug Depend Date: 2021-05-12
Authors: Marilyn T Lake; Steven Shoptaw; Jonathan C Ipser; Sae Takada; Lara J van Nunen; Gosia Lipinska; Dan J Stein; Edythe D London Journal: Front Psychiatry Date: 2020-02-18 Impact factor: 4.157